Form 4: Cardiff Oncology Director Rodney S. Markin Reports Stock Option Grant

Director Rodney S. Markin of Cardiff Oncology, Inc. reports the acquisition of 29,700 stock options on June 27, 2024.

Summary

• Rodney S. Markin, a director of Cardiff Oncology, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on June 27, 2024.
• Markin acquired 29,700 stock options with an exercise price of $2.33.
• These options become exercisable on June 27, 2025, and expire on June 27, 2034.
• Following the reported transaction, Markin directly owns 182,027 shares of Cardiff Oncology, Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating stock option grants to a director, which can be seen as a positive sign of alignment with shareholder interests, but doesn't provide strong positive or negative signals.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates changes in the director's holdings of Cardiff Oncology stock.

Stakeholder Impact

• The acquisition of stock options by a director may have a slightly positive impact on shareholder sentiment.

Key Dates